NCT04921930

Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)

Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich Ataxia

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France · Other Government
• Sex: Male
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of Friedreich ataxia. It will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial

Conditions

• Friedreich Ataxia

Interventions

Type	Name	Description
DRUG	Artesunate Oral Product	Dose escalation intake of artesunate

Timeline

• Start date: 2022-05-06
• Primary completion: 2024-04-17
• Completion: 2024-04-17
• First posted: 2021-06-10
• Last updated: 2024-07-30

Locations

1 site across 1 country: France